58 research outputs found
Radioimmunotherapy for mantle cell lymphoma : 5-year follow-up of 90 patients from the international RIT registry
To assess the efficacy of radioimmunotherapy (RIT) wit
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
Ibrutinib may inhibitintestinal CYP3A4 and induce CYP2B6 and/or CYP3A. Secondary
to potential induction, ibrutinib may reduce the exposure and effectiveness of oral
contraceptives (OCs). This phase I study evaluated the effect of ibrutinib on the pharmacokinetics of the CYP2B6 substrate bupropion, CYP3A substrate midazolam, and
OCs ethinylestradiol (EE) and levonorgestrel (LN). Female patients (N = 22) with B-cell
malignancies received single doses of EE/LN (30/150 μg) and bupropion/midazolam
(75/2 mg) during a pretreatment phase on days 1 and 3, respectively (before starting ibrutinib on day 8), and again after ibrutinib 560 mg/day for ≥ 2 weeks. Intestinal
CYP3A inhibition was assessed on day 8 (single-dose ibrutinib plus single-dose midazolam). Systemic induction was assessed at steady-state on days 22 (EE/LN plus ibrutinib) and 24 (bupropion/midazolam plus ibrutinib). The geometric mean ratios (GMRs;
test/reference) for maximum plasma concentration (Cmax) and area under the plasma
concentration-time curve (AUC) were derived using linear mixed-effects models (90%
confidence interval within 80%-125% indicated no interaction). On day 8, the GMR
for midazolam exposure with ibrutinib coadministration was ≤ 20% lower than the reference, indicating lack of intestinal CYP3A4 inhibition. At ibrutinib steady-state, the
Cmax and AUC of EE were 33% higher than the reference, which was not considered
clinically relevant. No substantial changes were noted for LN, midazolam, or bupropion. No unexpected safety findings were observed. A single dose of ibrutinib did not
inhibit intestinal CYP3A4, and repeated administration did not induce CYP3A4/2B6,
as assessed using EE, LN, midazolam, and bupropion
Current status and achievements of Polish haemato-oncology
The number of newly diagnosed haematological malignancies in Polish adults and children is about 9,000 a year, which constitutes about 5.5% of all malignancies in the country. Adult patients with haematological malignancies are diagnosed and treated in 42 institutions in Poland. The scientific and educational support for this activity is provided under the umbrella of the Polish Society of Haematologists and Transfusiologists (PTHiT, Polskie Towarzystwo Hematologów i Transfuzjologów), the Polish Adult Leukemia Group (PALG), the Polish Lymphoma Research Group (PLRG), the Polish Myeloma Study Group (PMSG), the Polish Myeloma Consortium (PMC), and consultants in haematology. The aim of this position paper is to present the current status and progress in therapy of haematological malignancies in Polish haematology adult centres, focusing on the activity of PALG, PLRG, and PMSG. The achievements of Polish haemato-oncology at the beginning of the third decade of the 21st century are set out in this paper. Polish haemato-oncology today has an important international position based on contributions to the development of knowledge, international cooperation, and a high quality of patient care. In many instances, clinical trials run by Polish collaborative groups have influenced international standards. Polish haematologists have been the authors of treatment recommendations, and their research has indicated areas for further research
Konsensus ekspertów Polskiej Grupy Badawczej Chłoniaków w zakresie postępowania w nawrotowym lub opornym na leczenie klasycznym chłoniaku Hodgkina w 2020 roku
In Poland, 800–900 new cases of classical Hodgkin’s lymphoma (cHL) are diagnosed annually. Despite relatively good results of first-line treatment, 20–25% of patients relapse and the chances of their cure become much smaller. The paper presents the consensus of the Polish experts on the management of patients with relapsed and refractory cHL in 2020, taking into account generally accepted international recommendations, approved indications and the Polish reimbursement conditions. The proposed recommendations were voted by all authors. The recommendations that were agreed by the majority are presented in the paper. For each recommendation, the most important information supporting its legitimacy and information justifying the dissenting opinions of the authors of the consensus were quoted.W Polsce rozpoznaje się rocznie 800–900 chorych na klasycznego chłoniaka Hodgkina (cHL). Mimo relatywnie bardzo dobrych wyników leczenia pierwszej linii u 20–25% chorych dochodzi do nawrotu choroby i szanse na ich wyleczenie stają się znacznie mniejsze. W pracy przedstawiono konsensus polskich ekspertów dotyczący postępowania u chorych na nawrotowego i opornego na leczenie cHL w 2020 roku, uwzględniając ogólnie przyjęte zalecenia międzynarodowe, wskazania rejestracyjne oraz polskie warunki refundacyjne. Przedstawione rekomendacje poddano pod głosowanie autorów konsensusu. Rekomendacje, które zostały przyjęte wiekszością w głosowaniu, przedstawiono w pracy. Przy każdej rekomendacji przywołano najważniejsze informacje przemawiające za jej zasadnością oraz informacje uzasadniające zdania odrębne autorów konsensusu
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma : Final Results of a Randomized Phase III Study
Introduction: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from rituximab to CT-P10. Patients and Methods: LTBFL patients were randomized (1:1) to receive CT-P10 or rituximab (375 mg/m intravenously; day 1 of 4 7-day cycles). Patients achieving disease control entered a 2-year maintenance period. CT-P10 or rituximab were administered every 8 weeks (6 cycles) in year 1; all patients could receive CT-P10 (every 8 weeks; 6 cycles) in year 2. Secondary endpoints (reported here) were overall response rate (ORR) during the study period, progression-free survival (PFS), time to progression (TTP), and overall survival (OS). Safety and immunogenicity were evaluated. Results: Between November 9, 2015 and January 4, 2018, 258 patients were randomized (130 for CT-P10; 128 for rituximab). ORR was similar between groups over the study period (CT-P10: 88%; rituximab: 87%). After 29.2 months' median follow-up, median PFS, TTP, and OS were not estimable; 24-month Kaplan-Meier estimates suggested similarity between groups. Overall, 114 (CT-P10: 88%), and 104 (rituximab: 81%) patients experienced treatment-emergent adverse events. The single switch was well tolerated. Conclusion: These updated data support therapeutic similarity of CT-P10 and rituximab and support the use of CT-P10 monotherapy for previously untreated LTBFL
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
Ibrutinib may inhibitintestinal CYP3A4 and induce CYP2B6 and/or CYP3A. Secondary
to potential induction, ibrutinib may reduce the exposure and effectiveness of oral
contraceptives (OCs). This phase I study evaluated the effect of ibrutinib on the pharmacokinetics of the CYP2B6 substrate bupropion, CYP3A substrate midazolam, and
OCs ethinylestradiol (EE) and levonorgestrel (LN). Female patients (N = 22) with B-cell
malignancies received single doses of EE/LN (30/150 μg) and bupropion/midazolam
(75/2 mg) during a pretreatment phase on days 1 and 3, respectively (before starting ibrutinib on day 8), and again after ibrutinib 560 mg/day for ≥ 2 weeks. Intestinal
CYP3A inhibition was assessed on day 8 (single-dose ibrutinib plus single-dose midazolam). Systemic induction was assessed at steady-state on days 22 (EE/LN plus ibrutinib) and 24 (bupropion/midazolam plus ibrutinib). The geometric mean ratios (GMRs;
test/reference) for maximum plasma concentration (Cmax) and area under the plasma
concentration-time curve (AUC) were derived using linear mixed-effects models (90%
confidence interval within 80%-125% indicated no interaction). On day 8, the GMR
for midazolam exposure with ibrutinib coadministration was ≤ 20% lower than the reference, indicating lack of intestinal CYP3A4 inhibition. At ibrutinib steady-state, the
Cmax and AUC of EE were 33% higher than the reference, which was not considered
clinically relevant. No substantial changes were noted for LN, midazolam, or bupropion. No unexpected safety findings were observed. A single dose of ibrutinib did not
inhibit intestinal CYP3A4, and repeated administration did not induce CYP3A4/2B6,
as assessed using EE, LN, midazolam, and bupropion
- …